Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Shares Outstanding (2016 - 2026)

Myriad Genetics has reported Shares Outstanding over the past 16 years, most recently at $93.5 million for Q4 2025.

  • Quarterly Shares Outstanding rose 2.41% to $93.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $93.5 million through Dec 2025, up 2.41% year-over-year, with the annual reading at $93.5 million for FY2025, 2.41% up from the prior year.
  • Shares Outstanding was $93.5 million for Q4 2025 at Myriad Genetics, roughly flat from $93.1 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $93.5 million in Q4 2025 and troughed at $76.7 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $82.0 million (2023), against an average of $85.4 million.
  • Year-over-year, Shares Outstanding increased 1.48% in 2023 and then grew 11.04% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $80.0 million in 2021, then rose by 1.5% to $81.2 million in 2022, then increased by 10.71% to $89.9 million in 2023, then increased by 1.56% to $91.3 million in 2024, then grew by 2.41% to $93.5 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Shares Outstanding are $93.5 million (Q4 2025), $93.1 million (Q3 2025), and $93.1 million (Q2 2025).